Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Advanced therapies
  • Virology
  • Bacteriology
  • Biotherapeutics
  • Analytical sciences
  • Diagnostics
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Advanced therapies  /  
  • Genomic reference materials  /  
  • WHO 1st International Standard for Cancer Genomes

Proposed 1st WHO International Standards for Cancer Genomes 

NIBSC is currently preparing the proposed WHO 1st International Standards for Cancer Genomes; three genomic DNAs of two cancer and one wildtype genomes.

These materials are intended as both calibrants in the quantification of (predicted) clinically-relevant variants
PIK3CA p.E454K, TP53 p.R306*, NRAS p.G12C, PTEN p.K267fs*9, and MAP2K1/MEK1 p.D67N, and as reference materials to validate assay performance with multiple other genome-wide variants in these pan-cancer materials.
Key staff

Dr Jennifer Boyle – Senior Scientist
Dr Pia Sanzone – Senior Scientist

Available standards

09/138 : BCR-ABL (WHO)
16/120 : JAK2 V617F (WHO)
16/250 : KRAS codons 12 and 13 (WHO)
11/218: Lynch/HNPCC (MLH1/MSH2; CE) 
04/224 : Factor V Leiden (WHO)
08/160 : Factor VIII intron 22 inversion (WHO) 
05/130: Prothrombin G20210A (Factor II; WHO)
08/158: Fragile X (WHO) 
09/140: Prader Willi and Angelman (WHO)
07/222: RhD/SRY Plasma DNA (WHO)
11/214: Red Blood Cell Genotyping (WHO)

Ordering genomic refrence materials

Further information on ordering genomic reference materials from NIBSC may be found here.

Contact us 

grmteam@nibsc.org

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap